This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$ 888 million AI-driven oncology collaboration with Servier. BioRay and Simcere Zaiming filed for Hong Kong IPOs to advance their pipelines, while Haisco secured a US$ 1 billion global licensing deal for its PDE3/4 inhibitor. Key clinical updates include MSD’s China approval for PAH drug Winrevair, breakthrough therapy designation for Doer Biologics’ DR10624, Hansoh’s aumolertinib gaining its fifth indication, and Akeso’s ivonescimab showing dual PFS/OS positive Phase III data. These developments reflect strong progress in China’s biotech innovation and partnerships.
